1. 406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. (9th November 2020) Authors: Yellin, Michael; Rawls, Tracey; Young, Diane; Golden, Philip; Vitale, Laura; He, Li-Zhen; Thomas, Lawrence; Keler, Tibor Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. (9th November 2020) Authors: Yellin, Michael; Rawls, Tracey; Young, Diane; Golden, Philip; Vitale, Laura; He, Li-Zhen; Thomas, Lawrence; Keler, Tibor Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors. (7th November 2013) Authors: Ansell, Stephen; Northfelt, Donald; Flinn, Ian; Burris, Howard; Dinner, Shira; Villalobos, Victor; Sikic, Branimir; Pilja, Lana; Yellin, Michael; Keler, Tibor; Davis, Thomas Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors. (7th November 2013) Authors: Burris, Howard; Ansell, Stephen; Neumanitis, John; Weiss, Geoffrey; Sikic, Branimir; Northfelt, Donald; Pilja, Lana; Davis, Thomas; Yellin, Michael; Keler, Tibor; Bullock, Timothy Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Issue 3 (5th March 2013) Authors: Mayer, Lloyd; Sandborn, William J; Stepanov, Yuriy; Geboes, Karel; Hardi, Robert; Yellin, Michael; Tao, Xiaolu; Xu, Li An; Salter-Cid, Luisa; Gujrathi, Sheila; Aranda, Richard; Luo, Allison Y Journal: Gut Issue: Volume 63:Issue 3(2014) Page Start: 442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS. (5th November 2018) Authors: Reardon, David; Kaley, Thomas; Iwamoto, Fabio; Baehring, Joachim; Subramaniam, Deepa; Rawls, Tracey; He, Yi; Keler, Tibor; Yellin, Michael Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 6 Page Start: vi6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity. (6th November 2014) Authors: Bullock, Timothy; McClintic, Hillary; Jeong, Se; Smith, Kelly; Olson, Walt; Ramakrishna, Venky; Vitale, Laura; Green, Jennifer; Yellin, Michael; Davis, Thomas; Keler, Tibor Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Issue 8 (8th August 2022) Authors: Sanborn, Rachel E; Pishvaian, Michael J; Callahan, Margaret K; Weise, Amy; Sikic, Branimir I; Rahma, Osama; Cho, Daniel C; Rizvi, Naiyer A; Sznol, Mario; Lutzky, Jose; Bauman, Julie E; Bitting, Rhonda L; Starodub, Alexander; Jimeno, Antonio; Reardon, David A; Kaley, Thomas; Iwamoto, Fabio; Baehri... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗